Clinigen Group (CLIN) Stock Rating Reaffirmed by N+1 Singer

N+1 Singer restated their buy rating on shares of Clinigen Group (LON:CLIN) in a report published on Wednesday. They currently have a GBX 1,225 ($16.41) price target on the stock.

CLIN has been the topic of a number of other research reports. Peel Hunt upgraded shares of Clinigen Group to a buy rating and lifted their price target for the stock from GBX 1,200 ($16.07) to GBX 1,350 ($18.08) in a report on Tuesday, October 10th. Berenberg Bank began coverage on shares of Clinigen Group in a report on Wednesday, November 1st. They issued a hold rating and a GBX 1,200 ($16.07) target price on the stock. Finally, Royal Bank Of Canada restated an outperform rating and issued a GBX 1,360 ($18.21) target price on shares of Clinigen Group in a report on Tuesday, November 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of GBX 1,200.83 ($16.08).

Clinigen Group (CLIN) opened at GBX 1,017.05 ($13.62) on Wednesday. Clinigen Group has a fifty-two week low of GBX 700 ($9.37) and a fifty-two week high of GBX 1,187 ($15.90).

Clinigen Group (LON:CLIN) last issued its quarterly earnings results on Thursday, September 28th. The company reported GBX 41.80 ($0.56) EPS for the quarter, topping analysts’ consensus estimates of GBX 41.20 ($0.55) by GBX 0.60 ($0.01). The company had revenue of £302.30 million for the quarter. Clinigen Group had a net margin of 0.70% and a return on equity of 0.98%.

The company also recently announced a dividend, which was paid on Friday, December 1st. Investors of record on Thursday, November 9th were issued a GBX 3.40 ($0.05) dividend. This is a positive change from Clinigen Group’s previous dividend of $1.60. The ex-dividend date of this dividend was Thursday, November 9th. This represents a yield of 0.32%.

In related news, insider John Bacon sold 250,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of GBX 1,093 ($14.64), for a total value of £2,732,500 ($3,659,434.85). Also, insider Shaun Edward Chilton sold 100,000 shares of the business’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of GBX 1,150 ($15.40), for a total transaction of £1,150,000 ($1,540,109.82). In the last 90 days, insiders sold 354,955 shares of company stock worth $393,289,235.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/12/03/clinigen-group-clin-stock-rating-reaffirmed-by-n1-singer.html.

About Clinigen Group

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply